Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial

Study objectives TLD-1 is a novel pegylated liposomal doxorubicin (PLD) formulation aiming to optimise the PLD efficacy-toxicity ratio. We aimed to characterise TLD-1’s population pharmacokinetics using non-compartmental analysis and nonlinear mixed-effects modelling. Methods The PK of TLD-1 was ana...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2024-09, Vol.94 (3), p.349-360
Hauptverfasser:	Mc Laughlin, Anna M., Hess, Dagmar, Michelet, Robin, Colombo, Ilaria, Haefliger, Simon, Bastian, Sara, Rabaglio, Manuela, Schwitter, Michael, Fischer, Stefanie, Eckhardt, Katrin, Hayoz, Stefanie, Kopp, Christoph, Klose, Marian, Sessa, Cristiana, Stathis, Anastasios, Halbherr, Stefan, Huisinga, Wilhelm, Joerger, Markus, Kloft, Charlotte
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibiotics, Antineoplastic - administration & dosage Antibiotics, Antineoplastic - pharmacokinetics Area Under Curve Cancer Research Clinical outcomes Clinical trials Dosage Dose-response effects Dose-Response Relationship, Drug Doxorubicin Doxorubicin - administration & dosage Doxorubicin - analogs & derivatives Doxorubicin - pharmacokinetics Female Half-Life Humans Male Medicine Medicine & Public Health Metabolites Middle Aged Models, Biological NCT NCT03387917 Neoplasms - drug therapy nonlinear mixed effects models Oncology Original Original Article Pharmacokinetics Pharmacology/Toxicology Polyethylene Glycols - administration & dosage Polyethylene Glycols - pharmacokinetics Population studies Precision medicine Solid tumors surface area Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!